PRESS RELEASE
from UCB
UCB Media Room: Disposal of own shares
https://mb.cision.com/Public/18595/3635918/b92cf093d562c84f_800x800ar.png
** Disposal of own shares
------------------------------------------------------------
Brussels (Belgium), 23 September 2022 =E2=80=93 20:00 (CEST) =E2=80=93 Regu=
lated information=C2=A0
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members of its personnel, it has disposed of UCB shares =
OTC in view of deliveries of these shares to the relevant members of the pe=
rsonnel, within the framework of the Long-Term Incentive Program of the UCB=
Group, as follows:
https://mb.cision.com/Public/18595/3635918/94a83133193c39ab_800x800ar.png
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
antje.witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 600 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi=
llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
=C2=A0
GenericFile
220923 - Vervreemding van eigen aandelen NL (https://mb.cision.com/Public/1=
8595/3635918/a068a9c3e71fe17a.pdf) GenericFile
220923 - Disposals of own shares ENG (https://mb.cision.com/Public/18595/36=
35918/8a913fc5a4649aac.pdf) GenericFile
220923- Ali=C3=A9nation d actions propres FR (https://mb.cision.com/Public/=
18595/3635918/937444b4c0bb17e8.pdf) Image
Chart 1 Sept 23 2022 (https://mb.cision.com/Public/18595/3635918/94a8313319=
3c39ab_org.png)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x116885x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium